A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2) Metastatic, castration-resistant prostate cancer (mCRPC) with PSA value at screening =4 ng/mL that has progressed within 6 months prior t

You may not be eligible for this study if the following are true:

  • 1) Has received treatment with an approved systemic therapy within 3 weeks of dosing or has not yet recovered (ie, grade =1 or baseline) from any acute toxicities. 2) Has received any previous systemic biologic therapy within 5 half-lives of first dos


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.